Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN 5% vs TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Travasol 5.5% with electrolytes provides a source of amino acids and electrolytes for parenteral nutrition, supporting protein synthesis and maintaining metabolic balance.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
Intravenous: 500 mL to 2 L per day, infused at a rate of 20-40 mL/kg/day (0.5-1.5 g amino acids/kg/day) based on metabolic needs and tolerance.
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Not applicable; components are endogenous and rapidly cleared. Amino acids have short half-lives (e.g., alanine ~15 min; leucine ~30 min) and are continuously metabolized. Terminal elimination of water and electrolytes follows body fluid kinetics.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Primarily renal; 90-100% eliminated as free amino acids, electrolytes, and water. Metabolized nitrogen is excreted as urea. Biliary/fecal: negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution